Determinants of health related quality of life and health state utility in patients with age related macular degeneration: the association of contrast sensitivity and visual acuity

Bansback, Nick; Czoski-Murray, Carolyn; Carlton, Jill; Lewis, Grace M.; Hughes, Lindsey; Espallargues, Mireia; Brand, Christopher; Brazier, John

doi:10.1007/s11136-006-9126-8

Cited by 70 publications

(65 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our finding of a better CS at baseline being associated with better BCVA during follow-up raises questions regarding the differential predictive effect of different types of visual function. Our findings, supported by others, [14][15][16][17] suggest that CS should be used to a greater extent in assessing the efficacy of treatment of AMD.…”

Section: Discussionsupporting

confidence: 88%

Baseline clinical measures and early response predict success in verteporfin photodynamic therapy for neovascular age-related macular degeneration

Garcı́a-Fiñana

Murjaneh

Mahmood

et al. 2010

Eye

View full text Add to dashboard Cite

Purpose To analyse the influence of baseline clinical characteristics on the outcome of verteporfin photodynamic therapy (VPDT) for neovascular age-related macular degeneration (nAMD). Methods A total of 1008 patients commencing VPDT for nAMD in a single UK centre entered a prospective observational study between 1999 and 2006 and were followed for 2 years. Longitudinal linear mixed-effects modelling was applied to assess the influence of baseline covariates, such as best corrected visual acuity (BCVA), contrast sensitivity (CS), age, lesion size, and lesion type, on changes of BCVA over time in patients after VPDT. A logistic regression analysis was used to analyse clinical features significantly associated with treatment failure. Results Study eye BCVA was significantly better on average throughout the course of treatment in patients with better baseline BCVA and CS in the study eye (Po0.001 and Po0.01, respectively) and lower age (P ¼ 0.01). Mean BCVA showed a significant reduction over time with a significant quadratic relationship between 0 and 6 months and with stabilisation between 6 and 9 months. Patients with better BCVA and worse CS at baseline, and those in whom BCVA dropped during the first 3 months of follow-up, were more likely to lose X15 letters after 12 months.Conclusions Findings from our large longitudinal data set provide estimates of likely outcome based on baseline features and response at 3 months in patients commencing a course of VPDT for nAMD. Statistical modelling built up for this large data set can be applicable to other studies in ophthalmology research.

show abstract

Section: Discussionsupporting

confidence: 88%

Baseline clinical measures and early response predict success in verteporfin photodynamic therapy for neovascular age-related macular degeneration

Garcı́a-Fiñana

Murjaneh

Mahmood

et al. 2010

Eye

View full text Add to dashboard Cite

show abstract

“…Visual discomfort in performing daily activities often occurs in patients with AMD even though they have a BCVA of 0.00 logMAR on Snellen charts. This vision quality loss is seen in early AMD before any detectable retinal changes occur (18,37) . CS reduction in AMD patients becomes more evident and uncomfortable under conditions of low illumination, which provides a low contrast environment (16) .…”

Section: Discussionmentioning

confidence: 99%

“…CS decreases in all stages of glaucoma and age-related macular degeneration (AMD) have been documented using different testing methods (7,(12)(13)(14)(15) . Glaucoma, cataract, and AMD patients suffer from pro blems in vision-related activities of daily living and the inability to recognize targets in real world, which can be better identified by CS tests than by visual acuity tests (14,(16)(17)(18) . The increasing importance of visual quality and the need for accurate measurement of visual acuity has led to more interest in CS tests (12,(19)(20)(21) .…”

Section: Introductionmentioning

confidence: 99%

Repeatability of contrast sensitivity testing in patients with age-related macular degeneration, glaucoma, and cataract

Kara¹,

Gencer²,

Erşan³

et al. 2016

Arquivos Brasileiros De Oftalmologia

View full text Add to dashboard Cite

Approved by the following research ethics committee: Canakkale Onsekiz Mart University (#050. 99-151). ABSTRACTPurpose: To analyze the intrasession and intersession repeatability of contrast sensitivity (CS) measurements in patients with glaucoma, cataract, or age-related macular degeneration (AMD) and healthy controls. Methods: CS measurements were performed using the OPTEC-Functional Vision Analyzer (FVA), which uses a standardized and closed (view-in) system. Measurements for patients with glaucoma, cataract, or AMD and healthy controls were repeated within 30 minutes (intrasession) and during two sessions (intersession), separated by one week to one month. Test-retest reliability and correlation were measured using the intraclass correlation coefficient (ICC) and coefficient of repeatability (COR). Results: Ninety subjects (90 eyes) with visual acuity of 0.17 logMAR or higher in the cataract group or 0.00 logMAR in the other groups were included. During the first session, the ICC values were 0.87, 0.90, 0.76, and 0.69, and COR values were 0.24, 0.20, 0.38, and 0.25 for the control, glaucoma, cataract, and AMD groups, respectively. The reliability scores significantly improved during the second session, except in the glaucoma group. There was an acceptable floor effect and no ceiling effect at higher frequencies in the glaucoma and AMD groups. Conclusion: In subjects with good visual acuity, the FVA system is useful for evaluating CS and demonstrates good repeatability, as shown by ICC and COR. Because there is no ceiling effect, this system is beneficial for evaluation of early changes in CS, particularly in patients with glaucoma or AMD.Keywords: Macular degeneration; Contrast sensitivity; Glaucoma; Age effect; Repro ducibility of results , glaucoma, catarata e AMD foram, respectivamente, ICC 0,87; 0,90; 0,76; 0,69, e COR 0,24; 0,20; 0,38; 0,25 RESUMO Objetivo: Analisar a reprodutibilidade intrassessão e intersessão das medidas de sen sibilidade ao contraste (CS) em pacientes com degeneração macular relacionada à idade (AMD), glaucoma e catarata. Método: As medidas de CS foram feitas pelo OPTEC-Funcional Visão Analyzer (FVA), que utiliza um sistema padronizado e fechado de avaliação da acuidade visual. Medidas em pacientes com AMD, glaucoma, catarata e nos controles saudáveis foram repetidas no prazo de 30 minutos (intrassessão) em duas visitas (intersessão), separadas por uma semana a um mês. A confiabilidade e correlação teste-reteste foram calculados por meio do coeficiente de correlação intraclasse (ICC) e coeficiente de reprodutibilidade (COR). Resultados: Noventa olhos de 90 indivíduos foram recrutados com acuidade visual de 0,17 logMAR ou melhor em catarata e 0,00 logMAR nos outros grupos. A confiabilidade da CS na primeira visita dos grupos normal

show abstract

“…Within study (TT Chan et al [38] Screening Dakin et al [41] Ranibizumab and bevacizumab for AMD United Kingdom Within study (EQ Elshout et al [42] Aflibercept for AMD Netherlands Within study (H Butt et al [43] Bevacizumab for AMD United Kingdom Espallargues 200…”

Section: Chinamentioning

confidence: 99%

Health State Utility Values for Age-Related Macular Degeneration: Review and Advice

Butt

Tufail

Rubin

2016

Appl Health Econ Health Policy

View full text Add to dashboard Cite

Health state utility values are a major source of uncertainty in economic evaluations of interventions for age-related macular degeneration (AMD). This review identifies and critiques published utility values and methods for eliciting de-novo utility values in AMD. We describe how utility values have been used in health care decision making and provide guidance on the choice of utility values for future economic evaluations for AMD. Literature was searched using PubMed and health technology assessments (HTA) were searched using HTA agency websites to identify articles reporting utility values or approaches to derive utility values in AMD and articles applying utility values for use in health care decision making.s71 studies qualified for data extraction of which 22 were classified as containing utility values and/or elicitation methods relevant to AMD, while 49 were classified as using utility values in decision-making. A large number of studies have elicited utility values for AMD, although those applied to decision making have focused on a few of these. There is an appreciation of the challenges in the measurement and valuation of health states, with recent studies addressing challenges such as the insensitivity of generic health-related quality of life (HRQoL) questionnaires and utility in the worse seeing eye. We would encourage careful consideration when choosing utility values in decision making and an explicit critique of their applicability to the decision problem. Key Points for Decision Makers: There is a large body of literature describing utility values in AMD. Cost-utility analysis has been widely used to assess relative value of these interventions. A recent review of economic models comparing treatments for AMD identified 36 studies of which all but 3 reported costs per quality-adjusted life year (QALY). [2] QALYs are calculated by weighting each year of life lived using a utility score. Utility scores are anchored so that 1 is perfect health and 0 is equivalent to the state of death. Multiplying time in a health state by the health state utility value, 1 year of life lived in perfect health is equal to 1 QALY.[3]The term 'utility' in cost-utility analysis and its theory is based on von NeumannMorgenstern (vN-M) utility theory. The normative model for utility theory, the model for how a rational individual ought to behave, is that utility scores represent the strength of an individual's preference when faced with uncertainty for a given outcome, in this case a health state. A PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) scheme (Table 1) illustrates the included studies after title/abstract and full text reviews. Of the 206 studies identified, 113 studies were excluded after review of abstracts and titles. Reasons for exclusion included the topic not relating to utility, the disease not covering AMD, there being no primary data (e.g. letter or review) and the language not being English. After full text review, a further 23 studies were excluded due to the...

show abstract

Determinants of health related quality of life and health state utility in patients with age related macular degeneration: the association of contrast sensitivity and visual acuity

Cited by 70 publications

References 18 publications

Baseline clinical measures and early response predict success in verteporfin photodynamic therapy for neovascular age-related macular degeneration

Baseline clinical measures and early response predict success in verteporfin photodynamic therapy for neovascular age-related macular degeneration

Repeatability of contrast sensitivity testing in patients with age-related macular degeneration, glaucoma, and cataract

Health State Utility Values for Age-Related Macular Degeneration: Review and Advice

Contact Info

Product

Resources

About